EUVIMEDEUVIMED entdecken
Crossref

Rational Design of 6‐Amino‐2‐Piperazinylpyridine‐Based ROCK2 Inhibitors With Anti‐Breast Cancer Metastatic Efficiency

Haoran Chen, Shuqi Wang, Shanbao Bu, Zhi Cao, Xue Fan, Nan Jiang, Xin Zhai iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Haoran Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical Uni…. Hauptthemen laut MEDLINE: rho-Associated Kinases, Breast Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 25 Literaturangaben. Gefördert von: This study was supported by the Youth Backbone Talent Training Project of Shenyang Pharmaceutical University (No. ZQN202304) and the National Training Program….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rho‐associated coiled coil kinase (ROCK) plays a pivotal role in regulating actin cytoskeleton remodeling and cellular motility, establishing it as a promising therapeutic target for metastatic breast cancer. Guided by the lead compound belumosudil, a novel series of ROCK2 inhibitors based on a 6‐amino‐2‐piperazine pyridine scaffold was designed and synthesized. The Kinase‐Glo assay identified compound 14r as the most potent analog, showing an IC 50 value of 82.6 nM, which represented a 1.2‐fold improvement over belumosudil. Furthermore, the morphology of MDA‐MB‐231 cells treated with 14r was significantly changed in immunofluorescent staining analysis. Simultaneously, cell scratch experiments showed that 14r inhibited the migration of MDA‐MB‐231 cells in a dose‐dependent manner. Additionally, molecular docking studies elucidated the binding mode of 14r within the ROCK2 ATP pocket, corroborating its nanomolar‐level inhibitory activity. In conclusion, 14r showed great potential for further optimization to suppress breast cancer metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesBreast NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsDrug DesignPyridinesPiperazinesHumansStructure-Activity RelationshipFemaleMolecular Docking SimulationDose-Response Relationship, DrugMolecular StructureCell Line, TumorCell MovementDrug Screening Assays, AntitumorCell Proliferation

Stichwörter der Autor:innen

6‐amino‐2‐piperazinylpyridineROCK2breast cancer metastasisinhibitorssynthesis

Substanzen

rho-Associated KinasesROCK2 protein, humanAntineoplastic AgentsProtein Kinase InhibitorsPyridinesPiperazines

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.

ORCID-Profile: Xin Zhai

Förderung

  • This study was supported by the Youth Backbone Talent Training Project of Shenyang Pharmaceutical University (No. ZQN202304) and the National Training Program…

Zitieren

APA

Chen, H., Wang, S., Bu, S., Cao, Z., Fan, X., Jiang, N., & Zhai, X. (2025). Rational Design of 6‐Amino‐2‐Piperazinylpyridine‐Based ROCK2 Inhibitors With Anti‐Breast Cancer Metastatic Efficiency. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70068

Vancouver

Chen H, Wang S, Bu S, Cao Z, Fan X, Jiang N, et al. Rational Design of 6‐Amino‐2‐Piperazinylpyridine‐Based ROCK2 Inhibitors With Anti‐Breast Cancer Metastatic Efficiency. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70068

BibTeX
@article{Chen2025,
  author = {Chen, Haoran and Wang, Shuqi and Bu, Shanbao and Cao, Zhi and Fan, Xue and Jiang, Nan and Zhai, Xin},
  title = {Rational Design of 6‐Amino‐2‐Piperazinylpyridine‐Based ROCK2 Inhibitors With Anti‐Breast Cancer Metastatic Efficiency},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70068}
}
Kostenlos starten →